SYRE
Price
$17.38
Change
+$0.60 (+3.58%)
Updated
Aug 22 closing price
Capitalization
1.05B
75 days until earnings call
VYNE
Price
$0.33
Change
+$0.01 (+3.12%)
Updated
Aug 22 closing price
Capitalization
6.6M
Interact to see
Advertisement

SYRE vs VYNE

Header iconSYRE vs VYNE Comparison
Open Charts SYRE vs VYNEBanner chart's image
Spyre Therapeutics
Price$17.38
Change+$0.60 (+3.58%)
Volume$805.61K
Capitalization1.05B
VYNE Therapeutics
Price$0.33
Change+$0.01 (+3.12%)
Volume$1.48M
Capitalization6.6M
SYRE vs VYNE Comparison Chart in %
Loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SYRE vs. VYNE commentary
Aug 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Buy and VYNE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2025
Stock price -- (SYRE: $17.38 vs. VYNE: $0.33)
Brand notoriety: SYRE and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 125% vs. VYNE: 57%
Market capitalization -- SYRE: $1.05B vs. VYNE: $6.6M
SYRE [@Biotechnology] is valued at $1.05B. VYNE’s [@Biotechnology] market capitalization is $6.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.31B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileVYNE’s FA Score has 2 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • VYNE’s FA Score: 2 green, 3 red.
According to our system of comparison, VYNE is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 7 TA indicator(s) are bullish while VYNE’s TA Score has 5 bullish TA indicator(s).

  • SYRE’s TA Score: 7 bullish, 2 bearish.
  • VYNE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than VYNE.

Price Growth

SYRE (@Biotechnology) experienced а +2.54% price change this week, while VYNE (@Biotechnology) price change was -4.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +18.06%, and the average quarterly price growth was +26.94%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.05B) has a higher market cap than VYNE($6.6M). SYRE has higher P/E ratio than VYNE: SYRE (1.72) vs VYNE (0.71). SYRE YTD gains are higher at: -25.344 vs. VYNE (-90.030). VYNE has higher annual earnings (EBITDA): -42.58M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. VYNE (39.6M). SYRE has less debt than VYNE: SYRE (0) vs VYNE (25K). VYNE has higher revenues than SYRE: VYNE (476K) vs SYRE (0).
SYREVYNESYRE / VYNE
Capitalization1.05B6.6M15,899%
EBITDA-222.15M-42.58M522%
Gain YTD-25.344-90.03028%
P/E Ratio1.720.71242%
Revenue0476K-
Total Cash527M39.6M1,331%
Total Debt025K-
FUNDAMENTALS RATINGS
SYRE vs VYNE: Fundamental Ratings
SYRE
VYNE
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6198
P/E GROWTH RATING
1..100
841
SEASONALITY SCORE
1..100
1650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYNE's Valuation (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (72). This means that VYNE’s stock grew somewhat faster than SYRE’s over the last 12 months.

VYNE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that VYNE’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as VYNE (98). This means that SYRE’s stock grew similarly to VYNE’s over the last 12 months.

SYRE's Price Growth Rating (61) in the Pharmaceuticals Major industry is somewhat better than the same rating for VYNE (98). This means that SYRE’s stock grew somewhat faster than VYNE’s over the last 12 months.

VYNE's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for SYRE (84). This means that VYNE’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREVYNE
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSJRX68.401.05
+1.56%
Cohen & Steers Realty Shares R
KSMIX9.79N/A
N/A
Keeley Gabelli SMID Cap Value I
LGOPX27.02N/A
N/A
Lord Abbett Growth Opportunities P
RSIFX28.60N/A
N/A
Victory RS Science and Technology A
AFYCX25.95N/A
N/A
Bahl & Gaynor Income Growth C

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+3.58%
IDYA - SYRE
61%
Loosely correlated
+1.99%
CGON - SYRE
61%
Loosely correlated
+3.60%
BEAM - SYRE
58%
Loosely correlated
+3.94%
XNCR - SYRE
57%
Loosely correlated
+13.04%
CRNX - SYRE
56%
Loosely correlated
+5.17%
More

VYNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with NEVPF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
+3.47%
NEVPF - VYNE
52%
Loosely correlated
N/A
SYRE - VYNE
36%
Loosely correlated
+3.58%
ABVX - VYNE
34%
Loosely correlated
+3.83%
EYPT - VYNE
32%
Poorly correlated
+1.98%
CRDF - VYNE
31%
Poorly correlated
+2.65%
More